207 related articles for article (PubMed ID: 27799065)
1. A case study of an integrative genomic and experimental therapeutic approach for rare tumors: identification of vulnerabilities in a pediatric poorly differentiated carcinoma.
Dela Cruz FS; Diolaiti D; Turk AT; Rainey AR; Ambesi-Impiombato A; Andrews SJ; Mansukhani MM; Nagy PL; Alvarez MJ; Califano A; Forouhar F; Modzelewski B; Mitchell CM; Yamashiro DJ; Marks LJ; Glade Bender JL; Kung AL
Genome Med; 2016 Oct; 8(1):116. PubMed ID: 27799065
[TBL] [Abstract][Full Text] [Related]
2. Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response.
Beltran H; Eng K; Mosquera JM; Sigaras A; Romanel A; Rennert H; Kossai M; Pauli C; Faltas B; Fontugne J; Park K; Banfelder J; Prandi D; Madhukar N; Zhang T; Padilla J; Greco N; McNary TJ; Herrscher E; Wilkes D; MacDonald TY; Xue H; Vacic V; Emde AK; Oschwald D; Tan AY; Chen Z; Collins C; Gleave ME; Wang Y; Chakravarty D; Schiffman M; Kim R; Campagne F; Robinson BD; Nanus DM; Tagawa ST; Xiang JZ; Smogorzewska A; Demichelis F; Rickman DS; Sboner A; Elemento O; Rubin MA
JAMA Oncol; 2015 Jul; 1(4):466-74. PubMed ID: 26181256
[TBL] [Abstract][Full Text] [Related]
3. Personalized treatment based on mini patient-derived xenografts and WES/RNA sequencing in a patient with metastatic duodenal adenocarcinoma.
Zhao P; Chen H; Wen D; Mou S; Zhang F; Zheng S
Cancer Commun (Lond); 2018 Aug; 38(1):54. PubMed ID: 30139386
[TBL] [Abstract][Full Text] [Related]
4. Genomic alterations in BCL2L1 and DLC1 contribute to drug sensitivity in gastric cancer.
Park H; Cho SY; Kim H; Na D; Han JY; Chae J; Park C; Park OK; Min S; Kang J; Choi B; Min J; Kwon JY; Suh YS; Kong SH; Lee HJ; Liu ET; Kim JI; Kim S; Yang HK; Lee C
Proc Natl Acad Sci U S A; 2015 Oct; 112(40):12492-7. PubMed ID: 26401016
[TBL] [Abstract][Full Text] [Related]
5. Xenografts of primary human gynecological tumors grown under the renal capsule of NOD/SCID mice show genetic stability during serial transplantation and respond to cytotoxic chemotherapy.
Press JZ; Kenyon JA; Xue H; Miller MA; De Luca A; Miller DM; Huntsman DG; Gilks CB; McAlpine JN; Wang YZ
Gynecol Oncol; 2008 Aug; 110(2):256-64. PubMed ID: 18547621
[TBL] [Abstract][Full Text] [Related]
6. Integration of genomics, high throughput drug screening, and personalized xenograft models as a novel precision medicine paradigm for high risk pediatric cancer.
Tsoli M; Wadham C; Pinese M; Failes T; Joshi S; Mould E; Yin JX; Gayevskiy V; Kumar A; Kaplan W; Ekert PG; Saletta F; Franshaw L; Liu J; Gifford A; Weber MA; Rodriguez M; Cohn RJ; Arndt G; Tyrrell V; Haber M; Trahair T; Marshall GM; McDonald K; Cowley MJ; Ziegler DS
Cancer Biol Ther; 2018; 19(12):1078-1087. PubMed ID: 30299205
[TBL] [Abstract][Full Text] [Related]
7. Establishment and genetically characterization of patient-derived xenograft models of cervical cancer.
Zou S; Ye M; Zhang JA; Ji H; Chen Y; Zhu X
BMC Med Genomics; 2022 Sep; 15(1):191. PubMed ID: 36076209
[TBL] [Abstract][Full Text] [Related]
8. Application of patient-derived liver cancer cells for phenotypic characterization and therapeutic target identification.
Castven D; Becker D; Czauderna C; Wilhelm D; Andersen JB; Strand S; Hartmann M; Heilmann-Heimbach S; Roth W; Hartmann N; Straub BK; Mahn FL; Franck S; Pereira S; Haupts A; Vogel A; Wörns MA; Weinmann A; Heinrich S; Lang H; Thorgeirsson SS; Galle PR; Marquardt JU
Int J Cancer; 2019 Jun; 144(11):2782-2794. PubMed ID: 30485423
[TBL] [Abstract][Full Text] [Related]
9. Unstable Genome and Transcriptome Dynamics during Tumor Metastasis Contribute to Therapeutic Heterogeneity in Colorectal Cancers.
Cho SY; Chae J; Na D; Kang W; Lee A; Min S; Kang J; Choi B; Lee J; Sung CO; Chuang JH; Lee C; Lee WS; Park H; Kim JI
Clin Cancer Res; 2019 May; 25(9):2821-2834. PubMed ID: 30670495
[TBL] [Abstract][Full Text] [Related]
10. Genomic profile of metastatic breast cancer patient-derived xenografts established using percutaneous biopsy.
Kim S; Shin D; Min A; Kim M; Na D; Lee HB; Ryu HS; Yang Y; Woo GU; Lee KH; Lee DW; Kim TY; Lee C; Im SA; Kim JI
J Transl Med; 2021 Jan; 19(1):7. PubMed ID: 33407601
[TBL] [Abstract][Full Text] [Related]
11. Assessing the efficacy of targeting the phosphatidylinositol 3-kinase/AKT/mTOR signaling pathway in endometrial cancer.
Bradford LS; Rauh-Hain A; Clark RM; Groeneweg JW; Zhang L; Borger D; Zukerberg LR; Growdon WB; Foster R; Rueda BR
Gynecol Oncol; 2014 May; 133(2):346-52. PubMed ID: 24561032
[TBL] [Abstract][Full Text] [Related]
12. A comprehensively characterized large panel of head and neck cancer patient-derived xenografts identifies the mTOR inhibitor everolimus as potential new treatment option.
Klinghammer K; Raguse JD; Plath T; Albers AE; Joehrens K; Zakarneh A; Brzezicha B; Wulf-Goldenberg A; Keilholz U; Hoffmann J; Fichtner I
Int J Cancer; 2015 Jun; 136(12):2940-8. PubMed ID: 25404014
[TBL] [Abstract][Full Text] [Related]
13. Molecular heterogeneity of non-small cell lung carcinoma patient-derived xenografts closely reflect their primary tumors.
Wang D; Pham NA; Tong J; Sakashita S; Allo G; Kim L; Yanagawa N; Raghavan V; Wei Y; To C; Trinh QM; Starmans MH; Chan-Seng-Yue MA; Chadwick D; Li L; Zhu CQ; Liu N; Li M; Lee S; Ignatchenko V; Strumpf D; Taylor P; Moghal N; Liu G; Boutros PC; Kislinger T; Pintilie M; Jurisica I; Shepherd FA; McPherson JD; Muthuswamy L; Moran MF; Tsao MS
Int J Cancer; 2017 Feb; 140(3):662-673. PubMed ID: 27750381
[TBL] [Abstract][Full Text] [Related]
14. Combination therapy targeting both tumor-initiating and differentiated cell populations in prostate carcinoma.
Dubrovska A; Elliott J; Salamone RJ; Kim S; Aimone LJ; Walker JR; Watson J; Sauveur-Michel M; Garcia-Echeverria C; Cho CY; Reddy VA; Schultz PG
Clin Cancer Res; 2010 Dec; 16(23):5692-702. PubMed ID: 21138868
[TBL] [Abstract][Full Text] [Related]
15. Guidance to rational use of pharmaceuticals in gallbladder sarcomatoid carcinoma using patient-derived cancer cells and whole exome sequencing.
Feng F; Cheng Q; Yang L; Zhang D; Ji S; Zhang Q; Lin Y; Li F; Xiong L; Liu C; Jiang X
Oncotarget; 2017 Jan; 8(3):5349-5360. PubMed ID: 28029662
[TBL] [Abstract][Full Text] [Related]
16. Genomic and Functional Fidelity of Small Cell Lung Cancer Patient-Derived Xenografts.
Drapkin BJ; George J; Christensen CL; Mino-Kenudson M; Dries R; Sundaresan T; Phat S; Myers DT; Zhong J; Igo P; Hazar-Rethinam MH; Licausi JA; Gomez-Caraballo M; Kem M; Jani KN; Azimi R; Abedpour N; Menon R; Lakis S; Heist RS; Büttner R; Haas S; Sequist LV; Shaw AT; Wong KK; Hata AN; Toner M; Maheswaran S; Haber DA; Peifer M; Dyson N; Thomas RK; Farago AF
Cancer Discov; 2018 May; 8(5):600-615. PubMed ID: 29483136
[TBL] [Abstract][Full Text] [Related]
17. Influence of a novel histone deacetylase inhibitor panobinostat (LBH589) on the growth of ovarian cancer.
Garrett LA; Growdon WB; Rueda BR; Foster R
J Ovarian Res; 2016 Sep; 9(1):58. PubMed ID: 27633667
[TBL] [Abstract][Full Text] [Related]
18. Differential response to EGFR- and VEGF-targeted therapies in patient-derived tumor tissue xenograft models of colon carcinoma and related metastases.
Jin K; Lan H; Cao F; Han N; Xu Z; Li G; He K; Teng L
Int J Oncol; 2012 Aug; 41(2):583-8. PubMed ID: 22581265
[TBL] [Abstract][Full Text] [Related]
19. Colorectal cancer patient-derived xenografted tumors maintain characteristic features of the original tumors.
Cho YB; Hong HK; Choi YL; Oh E; Joo KM; Jin J; Nam DH; Ko YH; Lee WY
J Surg Res; 2014 Apr; 187(2):502-9. PubMed ID: 24332554
[TBL] [Abstract][Full Text] [Related]
20. Development of Personalized Therapeutic Strategies by Targeting Actionable Vulnerabilities in Metastatic and Chemotherapy-Resistant Breast Cancer PDXs.
Punzi S; Meliksetian M; Riva L; Marocchi F; Pruneri G; Criscitiello C; Orsi F; Spaggiari L; Casiraghi M; Della Vigna P; Luzi L; Curigliano G; Pelicci PG; Lanfrancone L
Cells; 2019 Jun; 8(6):. PubMed ID: 31216647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
